

## Antidiabetic Agents - Soliqua, Xultophy

- Insulins and Analogs and Incretin Mimetic Combinations
  - Soliqua (Insulin Glargine; Lixisenatide)
  - Xultophy (Insulin Degludec; Liraglutide)

### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

### Summary

Soliqua and Xultophy are both fixed combination antidiabetic therapies used to manage type 2 diabetes, a chronic medical condition characterized by high blood sugar levels due to insufficient production of insulin by the pancreas, or the body not responding effectively to insulin.

Soliqua is a combination of insulin glargine and lixisenatide, while Xultophy combines insulin degludec and liraglutide. Insulin glargine and insulin degludec are both long-acting insulin analogs, whereas lixisenatide and liraglutide are glucagon-like peptide-1 (GLP-1) receptor agonists. The latter class of drugs enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, thus assisting in the management of blood sugar levels.

Clinical trials have demonstrated the efficacy of both Soliqua and Xultophy. For instance, trials with insulin degludec/liraglutide (Xultophy) have shown that it is more effective than either drug alone in improving glycemic control, as determined by reductions in HbA1c, in patients with type 2 diabetes mellitus. In several studies, the fixed combination substantially improved glycemic control and achieved superior outcomes in HbA1c reduction compared to placebo or individual components. However, it should be noted that the use of this combination is not indicated for the treatment of diabetic ketoacidosis or type 1 diabetes mellitus.

Similarly, insulin glargine/lixisenatide (Soliqua) has been found to be more effective than either of its components alone in controlling blood sugar levels in type 2 diabetes patients. Clinical trials have shown a significantly greater reduction in HbA1c levels with the use of Soliqua compared to insulin glargine alone. Interestingly, while insulin therapy is often associated with weight gain, Soliqua therapy has been associated with weight loss.

Management of diabetes typically involves a combination of diet, exercise, and medication. When initial treatment with antihyperglycemic drugs like metformin is insufficient, adding or substituting with an SGLT2 inhibitor or a GLP-1 receptor agonist may be considered. In cases where these options prove inadequate, fixed-combination therapies like Soliqua and Xultophy may offer an effective alternative. These treatments offer the benefits of multiple antidiabetic agents, providing a more potent effect on blood glucose control.

**NOTE:**

1. The Plan requires that members either be unable to use, or have tried and failed preferred medication(s) first. Requests for non-formulary medications are subject to Non-Formulary Products Criteria (PG069).
2. Coverage for prescription medications intended for obesity treatment, weight loss, weight reduction, or dietary control is determined by each member's specific benefit policy. Please refer to the member's benefit plan document for information on benefit eligibility and terms of coverage. In cases where the plan includes coverage for drugs prescribed for obesity treatment or weight management, the Oscar Clinical Guideline: Weight Loss Agents (PG070) may also apply.

**Table 1: Antidiabetic Agents - Insulins and Analogs and Incretin Mimetic Combinations**

Classification	Drug <sup>#</sup>	FDA-Approved Indications
<b>Insulins and Analogs and Incretin Mimetic Combinations</b>	Soliqua (Insulin Glargine; Lixisenatide)	Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. <sup>1 2 3 4 5</sup>
	Xultophy (Insulin Degludec; Liraglutide)	Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. <sup>3 5 6 7</sup>

<sup>#</sup> include both brand and generic and all dosage forms and strengths unless otherwise stated

Limitations of Use:

<sup>1</sup> has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.

<sup>2</sup> is not recommended for use in combination with any other product containing a GLP-1 receptor agonist

<sup>3</sup> is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

<sup>4</sup> has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis.

<sup>5</sup> has not been studied in combination with prandial insulin.

<sup>6</sup> is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of the rodent C-cell tumor findings to humans.

<sup>7</sup> is not recommended for use in combination with any other product containing liraglutide or another (glucagon-like peptide-1) GLP-1 receptor agonist.

**Definitions**

**“Insulin”** is a hormone produced by the beta cells in the pancreas. It facilitates the entry of glucose into cells for energy production. Insufficient insulin leads to a high blood glucose level, a condition known as diabetes. Oral and injectable medications can help increase insulin production, enhance the body's sensitivity to insulin, and decrease blood sugar levels.

**“Type 1 Diabetes”** is an autoimmune condition where the pancreas's beta cells are unable to produce sufficient insulin, leading to elevated blood glucose levels. Patients with Type 1 diabetes often require daily insulin injections to regulate their blood glucose.

**“Type 2 Diabetes”** is a metabolic disorder characterized by insufficient insulin production or insulin resistance in the body cells. It is more common than Type 1 and often managed through lifestyle changes, non-insulin medications, and, if necessary, insulin injections.

“**Blood Glucose**” is the primary sugar found in the bloodstream, serving as the body's main energy source. Chronic high blood glucose levels can lead to complications from blood vessel damage.

“**Hemoglobin A1c (HbA1c)**” is a blood test that measures average blood glucose levels over the past 2 to 3 months. It is also referred to as the A1C or glycosylated hemoglobin test. Various factors, such as age, ethnicity, certain conditions, and pregnancy, can affect A1C results.

“**Hyperglycemia**” is the medical term for high blood glucose. It can occur due to inadequate fasting (fasting hyperglycemia) or post-meal (postprandial hyperglycemia).

“**Hypoglycemia**” is a condition characterized by abnormally low blood glucose, typically less than 70 mg/dL. Symptoms include hunger, nervousness, dizziness, confusion, and in severe cases, unconsciousness. Immediate treatment involves consuming carbohydrate-rich foods or using injectable glucagon for severe cases.

### Medical Necessity Criteria for Initial Authorization

The Plan considers **Insulins and Analogs and Incretin Mimetic Combinations** medically necessary when **ALL** the following criteria are met:

1. The medication is age-appropriate for the member as per the FDA-approved indications; **AND**
2. The member has a diagnosis of type 2 diabetes mellitus based on at least **ONE** of the following diagnostic criteria:
  - a. A fasting glucose level of greater than 126 mg/dL (7.0 mmol/L)\*; **and/or**
  - b. A 2-hour glucose tolerance test result of greater than 200 mg/dL (11.1 mmol/L)\*; **and/or**
  - c. A hemoglobin A1c (HbA1c) level of 6.5% (48 mmol/mol) or higher\*; **and/or**
  - d. Random plasma glucose  $\geq$  200 mg/dL (11.1 mmol/L) with classic symptoms of hyperglycemia (e.g., frequent urination, extreme thirst, and unexplained weight loss) or hyperglycemic crisis; **AND**

**Important Notes:** \*The American Diabetes Association (ADA) “Standards of Care in Diabetes” recommends, in the absence of unequivocal hyperglycemia, diagnosis requires two abnormal results from different tests which may be obtained at the same time (e.g., A1C and FPG), or the same test at two different time points.

- If two different tests are above diagnostic thresholds, this confirms the diagnosis without need for further testing.
- If two different tests are used and results are discordant, the test with a result above the diagnostic cut point should be repeated.

- *For the Random Plasma Glucose test, a confirmatory test is not required if accompanied by classic symptoms of hyperglycemia or hyperglycemic crisis.*
- 3. The member has **ONE** of the following:
  - a. is unable to use, or has adequately tried and failed metformin at a minimum effective dose of 1500 milligrams daily for 90 days; **or**
  - b. requires combination therapy **AND** has an A1c (hemoglobin A1c) of 7.5 percent or greater.

**If the above prior authorization criteria are met, the requested drug will be approved for 12-months.**

### **Medical Necessity Criteria for Re-authorization**

Reauthorization for 12 months will be granted if the member has been using the requested **Insulins and Analogs and Incretin Mimetic Combinations** and demonstrates an ongoing clinical need for continued therapy, as evidenced by **ONE** of the following:

1. A reduction in Hemoglobin A1c (HbA1c) since initiation of therapy, documented within the past 6 months; **or**
2. Maintenance of target HbA1c levels (e.g., HbA1c less than 7% or as determined by the treating provider based on member-specific goals); **or**
3. Improvement in fasting plasma glucose levels since initiation of therapy.

### **Experimental or Investigational / Not Medically Necessary**

Insulins and Analogs and Incretin Mimetic Combinations for any other indication is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven.

### **Appendix**

#### **Metformin in Type 2 Diabetes**

<sup>#</sup>The recommendation for a minimum effective dose of 1500 milligrams daily of metformin is derived from clinical findings which show that this dosage effectively regulates both fasting blood glucose and glycosylated hemoglobin levels - crucial markers of long-term glucose control.

Metformin functions by decreasing glucose production in the liver and enhancing insulin sensitivity in both the liver and peripheral tissues. This enhancement in turn improves the uptake and usage of

glucose. The efficacy of metformin is dose-dependent, with the most clinically meaningful responses usually not seen at doses below 1500 milligrams per day.

The strategy of starting metformin treatment at a lower dose and gradually stepping up the dose over time (typically over a period of weeks) is useful in reducing the occurrence and intensity of gastrointestinal side effects. These side effects are the most common adverse reactions linked with metformin therapy and can include symptoms such as nausea, vomiting, diarrhea, abdominal cramping, and bloating. Commencing therapy at a lower dose (for instance, 500 mg twice daily or 850 mg once daily) and progressively increasing the dosage over time allows patients to better tolerate metformin. This results in improved medication adherence and ultimately, superior glycemic control.

- For patients who need further glycemic control beyond what can be achieved with a total daily dose of 2000 mg, the dosage of metformin can be boosted up to a maximum of 2550 mg per day, given in divided doses. This upper limit is based on clinical trials that show doses above this level do not provide an additional glycemic control benefit but may increase the risk of adverse effects.
- For pediatric patients, the same principle of beginning at a lower dose and incrementally increasing applies, with a maximum limit of 2000 mg per day given in divided doses.

**Table 2: Metformin in Diabetes Treatment**

Clinical Consideration	Recommendation
Understanding Metformin	Metformin is frequently used due to its efficacy, cost-effectiveness, and cardiovascular benefits. However, GI adverse effects are common and could limit its use.
Managing Patient Expectations	Inform patients that side effects are often temporary and encourage patience during the dosage adjustment period.
Choosing Metformin Type	Extended-release (ER) versions are generally preferred due to fewer daily doses and reduced discontinuation rates. However, consider cost and insurance coverage.
Initiating Metformin	Start at a low dose (500 mg for ER/IR or 250 mg for those with GI intolerance history). Consider using liquid formulations or single-ingredient products for easier titration.
Dosage Increase	Gradually up titrate dosage every one to two weeks. Decrease back to the last tolerated dose if GI symptoms occur, and then try to increase more slowly.

Dosage Titration (Adults)	Dosage may be increased by 500 mg at weekly intervals until desired response or a maximum dosage is reached (2.55 g daily for immediate-release, 2.5 g for certain extended-release tablets, and 2 g for others).
Dosage Titration (Children 10–16 years)	Dosage may be increased by 500 mg at weekly intervals until desired response or a maximum dosage of 2 g daily in 2 divided doses is reached.
Maximizing Tolerance	Advise patients to take metformin during or immediately after meals. Consider dividing doses if tolerability is an issue.
Addressing Complaints	Manage common complaints such as diarrhea and nausea by temporary dose reduction. If odor of the drug is a problem, consider switching brands or generics.
GI Tolerance Issues	If GI symptoms persist, consider using 5-HT <sub>3</sub> -antagonists like ondansetron or treating underlying <i>Helicobacter pylori</i> infection.
Insufficient Dose Tolerance	Even lower doses can improve glucose control. Consider combining metformin with another agent if necessary.
Interrupted Therapy	If therapy is interrupted, consider a full titration when restarting. Lower the dose and increase slowly if adverse effects occur upon restarting.

**References**

1. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. *Obstet Gynecol.* 2018;131(2):e49-e64.
2. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. *Obstet Gynecol.* 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960
3. American Diabetes Association Professional Practice Committee; 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. *Diabetes Care* 1 January 2025; 48 (Supplement\_1): S27–S49. <https://doi.org/10.2337/dc25-S002>
4. American Diabetes Association Professional Practice Committee; 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. *Diabetes Care* 1 January 2025; 48 (Supplement\_1): S128–S145. <https://doi.org/10.2337/dc25-S006>
5. American Diabetes Association Professional Practice Committee; 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2025. *Diabetes Care* 1 January 2025; 48 (Supplement\_1): S167–S180. <https://doi.org/10.2337/dc25-S008>
6. American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. *Diabetes Care* 1 January 2025; 48 (Supplement\_1): S181–S206. <https://doi.org/10.2337/dc25-S009>

7. American Diabetes Association Professional Practice Committee; Summary of Revisions: Standards of Care in Diabetes—2025. *Diabetes Care* 1 January 2025; 48 (Supplement\_1): S6–S13. <https://doi.org/10.2337/dc25-SREV>
8. American Diabetes Association (ADA). Standards of medical care in diabetes–2021. *Diabetes Care*. 2021;44(suppl 1):S1-S232.
9. American Diabetes Association Professional Practice Committee, Draznin, B., Aroda, V. R., Bakris, G., Benson, G., Brown, F. M., Freeman, R., Green, J., Huang, E., Isaacs, D., Kahan, S., Leon, J., Lyons, S. K., Peters, A. L., Prahalad, P., Reusch, J., & Young-Hyman, D. (2022). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. *Diabetes care*, 45(Suppl 1), S125–S143. <https://doi.org/10.2337/dc22-S009>
10. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024 Jan 1;47(Suppl 1):S145-S157. doi: 10.2337/dc24-S008. PMID: 38078578; PMCID: PMC10725806.
11. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009. Erratum in: *Diabetes Care*. 2024 Jul 1;47(7):1238. doi: 10.2337/dc24-er07a. PMID: 38078590; PMCID: PMC10725810.
12. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. *Endocr Pract*. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002. Epub 2022 Aug 11. Erratum in: *Endocr Pract*. 2023 Jan;29(1):80-81. doi: 10.1016/j.eprac.2022.12.005. PMID: 35963508; PMCID: PMC10200071.
13. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2013;98(11):4227-4249.
14. Conlin PR, Burke BV, Hobbs C, Hurren KM, Lang AE, Morrison JW, Spacek L, Steil EN, Watts SA, Weinreb JE, Pogach LM. Management of Type 2 Diabetes Mellitus: Synopsis of the Department of Veterans Affairs and Department of Defense Clinical Practice Guideline. *Mayo Clin Proc*. 2024 Jul 5:S0025-6196(24)00210-6. doi: 10.1016/j.mayocp.2024.04.014. Epub ahead of print. PMID: 39093266.
15. David B Sacks, Mark Arnold, George L Bakris, David E Bruns, Andrea R Horvath, Åke Lernmark, Boyd E Metzger, David M Nathan, M Sue Kirkman, Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus, *Clinical Chemistry*, Volume 69, Issue 8, August 2023, Pages 808–868, <https://doi.org/10.1093/clinchem/hvad080>
16. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018;41(12):2669-2701. doi:10.2337/dci18-0033
17. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. *Diabetes Care* 2023; 46:S19.
18. Garber AJ, Handelsman Y, Grunberger G et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm 2020 executive summary. *Endocr Pract*. 2020; 26:107-139. [PubMed 32022600]



19. Grunberger G, Sherr J, Allende M, Blevins T, Bode B, Handelsman Y, Hellman R, Lajara R, Roberts VL, Rodbard D, Stec C, Unger J. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. *Endocr Pract.* 2021 Jun;27(6):505-537. doi: 10.1016/j.eprac.2021.04.008. PMID: 34116789.
20. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int.* 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019
21. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198
22. Qaseem A, Obley AJ, Shamliyan T, Hicks LA, Harrod CS, Crandall CJ; Clinical Guidelines Committee of the American College of Physicians; Balk EM, Cooney TG, Cross JT Jr, Fitterman N, Lin JS, Maroto M, Miller MC, Shekelle P, Tice JA, Tuft JE, Etxeandia-Ikobaltzeta I, Yost J. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. *Ann Intern Med.* 2024 May;177(5):658-666. doi: 10.7326/M23-2788. Epub 2024 Apr 19. PMID: 38639546; PMCID: PMC11614146.
23. Soliqua (insulin glargine/lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; June 2022.
24. Soliqua (insulin glargine/lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; September 2023.
25. Vaughan EM, Santiago-Delgado ZM. Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy. *Am Fam Physician.* 2024 Apr;109(4):333-342. PMID: 38648832.
26. Weinberg Sibony R, Segev O, Dor S, Raz I. Drug Therapies for Diabetes. *Int J Mol Sci.* 2023 Dec 5;24(24):17147. doi: 10.3390/ijms242417147. PMID: 38138975; PMCID: PMC10742594.
27. Xultophy (insulin degludec and liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2023.
28. Xultophy (insulin degludec and liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; June 2022.

### Clinical Guideline Revision / History Information

Original Date: 6/29/2023

**Reviewed/Revised:** 7/31/2023, 12/19/2024, 1/30/2025